PGEN
Precigen, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +1.8% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 910 | $7,453 | +1 | n/a |
| Q2 2026 | 80 | +1 | 77.32M | $440.58M | +8 | −7 |
| Q1 2026 | 82 | +6 | 77.19M | $298.23M | +8 | −2 |
| Q4 2025 | 75 | -2 | 85.66M | $358.05M | n/a | −2 |
| Q3 2025 | 16 | +1 | 41.97M | $138.07M | +2 | −1 |
| Q2 2025 | 12 | +2 | 40.00M | $56.80M | +2 | n/a |
| Q1 2025 | 7 | 0 | 18.74M | $27.92M | +1 | −1 |
| Q4 2024 | 7 | -3 | 18.78M | $21.04M | n/a | −3 |
| Q3 2024 | 9 | +1 | 17.66M | $16.73M | +1 | n/a |
| Q2 2024 | 8 | n/a | 6.84M | $10.80M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 11.28M | 0.0% | $16.01M | 0.0% | Held | 4 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 11.15M | n/a | $15.83M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 3 | The Vanguard Group ✦ (passive) | 9.07M | n/a | $12.88M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 3.75M | +7.8% | $5.32M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 3.03M | -0.3% | $4.30M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Marshall Wace ✦ | 369.14K | New | $524,176 | 0.0% | New | 1 | SEC ↗ ×2 |
| 7 | Fidelity (FMR) ✦ | 334.24K | n/a | $474,622 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 314.80K | New | $447,022 | 0.0% | New | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 287.40K | -63.8% | $408,112 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Millennium Management ✦ | 238.75K | +751.6% | $339,028 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 117.67K | +86.2% | $167,086 | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 12 | T. Rowe Price ✦ | 68.87K | +14.3% | $98,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $524,176 | 0.0% |
| Citadel Advisors | $447,022 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 204 holders, 132.74M shares, $508.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 3.41K sh @ 7.23 · $24,662
Open-market sales (S)
Director · 185.00K sh · $1.38M
Officer · 15.34K sh · $115,065
Officer · 79.17K sh · $593,745
Officer · 34.66K sh · $259,935
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology